Trial Profile
Pan-genotypic Direct Acting Antiviral Therapy in Donor HCV-positive to Recipient HCV-negative Liver Transplant
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 03 Aug 2022
Price :
$35
*
At a glance
- Drugs Sofosbuvir/velpatasvir (Primary)
- Indications Hepatitis C
- Focus Therapeutic Use
- 04 Jun 2021 Status changed from recruiting to discontinued as protocol transitioned to standard of care and no funding available to continue support of research work or data analysis.
- 31 Aug 2020 Planned End Date changed from 1 Sep 2021 to 1 Sep 2023.
- 31 Aug 2020 Planned primary completion date changed from 31 Dec 2020 to 31 Dec 2022.